【摘要】 目的：探讨比卡鲁胺联合戈舍瑞林治疗去势抵抗性前列腺癌的效果。方法：选择2021年1月—2024年9月金湖县人民医院收治的123例去势抵抗性前列腺癌患者（经会阴前列腺穿刺活检确诊）作为研究对象，以随机数字表法分为对照组61例，研究组62例。对照组采用比卡鲁胺治疗，研究组采用比卡鲁胺联合戈舍瑞林治疗。对比两组肿瘤标志物水平、免疫指标水平及不良反应发生率。结果：治疗前，两组总前列腺特异性抗原（tPSA）、游离前列腺特异性抗原（fPSA）水平比较，差异无统计学意义（P>0.05）；治疗后，两组tPSA、fPSA水平降低（P<0.05），且研究组低于对照组（P<0.001）。治疗前，两组辅助性T细胞1(Th1)、辅助性T细胞2(Th2)、Th1/Th2水平比较，差异无统计学意义（P>0.05）。治疗后，两组Th1、Th1/Th2水平升高（P<0.05），且研究组高于对照组（P<0.001）；两组Th2水平降低（P<0.05），且研究组低于对照组（P<0.001）。两组不良反应发生率对比，差异无统计学意义（P>0.05）。结论：比卡鲁胺联合戈舍瑞林治疗去势抵抗性前列腺癌的效果显著，能够降低肿瘤标志物水平并调节免疫平衡，且治疗安全性较高。更多还原

【Abstract】 Objective: To explore the efficacy of bicalutamide combined with goserelin in the treatment of castration-resistant prostate cancer. Methods: A total of one hundred and twenty-three patients with castration-resistant prostate cancer(diagnosed through transperineal prostate biopsy) admitted to Jinhu County People’s Hospital from January 2021 to September 2024 were selected as the research subjects. They were randomly divided into control group of sixty-one cases and study group of sixty-two cases using the random number table method. The control group was treated with bicalutamide, while the study group was treated with bicalutamide combined with goserelin. The levels of tumor markers, immune indicators, and the incidence of adverse reactions were compared between the two groups. Results: Before treatment, there was no statistically significant difference in the total prostate-specific antigen(tPSA) and free prostate-specific antigen(fPSA) levels between the two groups(P>0.05). After treatment, the levels of tPSA and fPSA in both groups decreased(P<0.05), and the levels in the study group were lower than those in the control group(P<0.001). Before the treatment, there was no statistically significant difference in the levels of helper T cell 1(Th1), helper T cell 2(Th2), and Th1/Th2 between the two groups(P>0.05). After the treatment, the levels of Th1 and Th1/Th2 in both groups increased(P<0.05), and the levels in the study group were higher than those in the control group(P<0.001). The levels of Th2 in both groups decreased(P<0.05), and the level in the study group was lower than that in the control group(P<0.001).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion:The combination of bicalutamide and goserelin has a remarkable effect in treating castration-resistant prostate cancer. It can reduce the levels of tumor markers and regulate the immune balance, and the treatment is also highly safe.更多还原